30 November 2012
Investments from its government and the international community continue; meanwhile, unhealthy lifestyles contribute to greater need for medications.
27 November 2012
The country still has enormous potential and is one of the few growing markets in what is a predominantly barren global economy. There is good cause for foreign businesses in Russia to be optimistic, not least in pharmaceuticals.
15 November 2012
Sberbank might invest up to $800 million to build a medical center in Moscow as part of a $1.5 billion hub presented Wednesday to upgrade the country's health care sector.
14 November 2012
Biotechnopark, which is currently under construction in Koltsovo near Novosibirsk, will establish a research center for collective use of upscale laboratory equipment for bacterial and viral researches. The question of further development of the Biotechnopark infrastructure was considered at a meeting of the regional government.
02 November 2012
A Russian venture-capital fund and an American investor have agreed to invest $2 million in VitaPortal, an online medical startup aiming to improve Russians' access to information on doctors, medicine and healthy living.
01 November 2012
New regulation in both countries will cut down registration procedures that can take up to 3 years, opening up new avenues.
28 October 2012
The Russian government plans to actively attract the world's largest pharmaceutical manufacturers to the country, through the creation of conditions to carry out clinical trials of their drugs in the country and providing their access to Russian patients, according to local media reports.
26 October 2012
Amid the falling dynamics in the European Union and the USA, Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) is considering a big expansion into the Russian pharmaceutical market, along with other BRIC (Brazil, Russia, India and China) markets, in the coming years.
22 October 2012
Cost and speed play big roles in the country’s increased presence in the market.
14 October 2012
“Few people disagree that small drug discovery companies are vital to the health of the UK's pharma industry, and central to the government's aim of innovation-led growth. But private backers have become increasingly risk-averse," said Ana Nicholls, Healthcare Analyst at the Economist Intelligence Unit in response to an article in the UK’s Financial Times yesterday, titled Pioneering research on drugs is key to clinching investment.
03 July 2020
03 July 2020
02 July 2020
02 July 2020